FMP
Kazia Therapeutics Limited
KZIA
NASDAQ
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
0.346 USD
0.0031 (0.895%)
About
ceo
Dr. John Edwin Friend II, M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.kaziatherapeutics.com
exchange
NASDAQ
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
CIK
0001075880
ISIN
US48669G1058
CUSIP
48669G105
Address
Three International Towers
Phone
1300 787 272
Country
AU
Employee
9
IPO Date
Jan 6, 1999
Key Executives
